Look at 5 individual CR/PR patients' narrative, they had lower disease burden overall, symptoms, spleen size, platelet count, etc. For example, only 2 out of 5 had baseline platelet count over 100x19^9/L, highest around 250, but INCY COMFORT-1 trial median baseline platelet count was 260! It would be interesting to see what Imetelstat response rate would be in similar population.
Market Data 
Markets 
AI
